For the biomedical industry, Bu Rixin told the reporter of science and technology innovation board Daily that the investment cycle of biomedicine is generally long, and it needs to go through multiple stages from research and development to listing.Among them, Chengdu Ruiyuan Semiconductor is mainly engaged in the research and development, design, packaging and sales of power management chips, and one of its main products is DC/DC chips. A-share listed companies include Jingfeng Mingyuan, Fumanwei, Shanghai Beiling and Xidiwei, all of which have certain market share and competitiveness in the DC/DC chip market.A 10 billion yuan M&A fund for biomedical industry will also be set up.
Big move! Shanghai's 10 billion integrated circuit design industry M&A fund has come.It is worth mentioning that the Action Plan also mentioned that if the "chain owner" enterprises carry out mergers and acquisitions around the key links of the industrial chain through enterprise venture capital (CVC), the establishment of CVC funds will be included in the fast track. At the same time, government investment funds can participate in M&A fund investment through common shares, preferred shares and convertible bonds, and make appropriate profits.The "10 billion yuan M&A fund for integrated circuit design industry" stated in the Action Plan is considered by the market as a supplement to the 100 billion yuan parent fund for the three leading industries.
"At present, the Yangtze River Delta has many excellent semiconductor enterprises and research institutions, while Shanghai has many top semiconductor design enterprises at home and abroad, such as Quanlun Electronics, Lanqi Technology, Fudan Microelectronics, Weir, Aojie Technology and Ziguang Zhanrui. The establishment of industrial mergers and acquisitions will help to integrate industry resources, promote industry agglomeration, and form a group of design companies with strength and key core technologies. " Yuan Shuai said.For the biomedical industry, Bu Rixin told the reporter of science and technology innovation board Daily that the investment cycle of biomedicine is generally long, and it needs to go through multiple stages from research and development to listing.Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14